This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. On Thursday, July 6, 2023, U.S. officials granted full approval to the closely watched Alzheimer’s drug, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease. (Eisai via AP, File)
By Matthew Perrone
U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Japanese drugmaker Eisai received conditional approval from the FDA in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease.
The FDA confirmed those results by reviewing data from a larger, 1,800-patient study in which the drug slowed memory and thinking decline by about five months in those who got the treatment, compared to those who got a dummy drug.
“This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease," said FDA's neurology drug director, Teresa Buracchio, in a statement.
The drug's prescribing information will carry the most serious type of warning, indicating that Leqembi can cause brain swelling and bleeding, side effects that can be dangerous in rare cases. The label notes that those problems are seen with other plaque-targeting Alzheimer's drugs.
The process of converting a drug to full FDA approval usually attracts little attention. But Alzheimer’s patients and advocates have been lobbying the federal government for months after Medicare officials announced last year they wouldn’t pay for routine use of Leqembi until it received FDA’s full approval.
There were concerns that the cost of new plaque-targeting Alzheimer's drugs like Leqembi could overwhelm the program's finances, which provide care for 60 million seniors. Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks.
The vast majority of Americans with Alzheimer’s get their health coverage through Medicare. And private insurers have followed its lead by withholding coverage for Leqembi and a similar drug, Aduhelm, until they receive FDA's full endorsement. An FDA decision on full approval for Aduhelm is still years away.
Medicare administrator, Chiquita Brooks-LaSure, has made clear the program will immediately begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements.
Medicare recipients getting Leqembi must be enrolled in a federal registry to track the drug's real-world safety and effectiveness. The information will help advance “knowledge of how these drugs can potentially help people,” Medicare officials said.
Hospitals and medical clinics have also cautioned that it may take time to get people started on the drug.
Doctors need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it. Nurses need to be trained to administer the drug and patients must be monitored with repeated brain scans to check for swelling or bleeding. The imaging and administration services carry extra costs for hospitals beyond the drug itself.
Eisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026. The drug is co-marketed with Cambridge, Massachusetts-based Biogen.
“We want to ensure that appropriate patients only are the ones that get this product,” said Alexander Scott, a vice president with Eisai.
Eisai studied the drug in people with early or mild disease who were evaluated using a scale measuring memory, thinking and other basic skills. After 18 months, those who got Leqembi declined more slowly — a difference of less than half a point on the scale — than participants who received a dummy infusion. Some Alzheimer's experts say that delay is likely too subtle for patients or their families to notice.
But federal health advisers said the difference could still be meaningful and recommended that FDA fully approve the drug at a public meeting in June.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Ellen Fitzsimmons-Craft, assistant professor of psychiatry at Washington University School of Medicine, joins Cheddar News to discuss how chatbots can help prevent eating disorders and the research that uncovered these findings.
Shoulder injuries are one of the most common orthopedic injuries – and they're also one of the most commonly ignored. But chimpanzees, with whom we share nearly 99% of our DNA, don’t encounter the same issues we do. So why are human shoulders such a design disaster? Well, we can trace the answer back to a very particular moment in our evolution.
As the Omicron variant continues to sweep across the country. The US Supreme Court is expected to hear arguments at the end of this week on whether or not the Biden administration can force private companies to vaccinate or test millions of their employees. In addition, the National Nurses United has spearheaded legal action to protect nurses and health care workers, patients, and the public while on the job. President of the National Nurses Union, Zenei Cortez, joined Cheddar to discuss more.
Digital medical care provider Pear Therapeutics rang the closing bell on the Nasdaq Friday and President and CEO Dr. Corey McCann, joined Cheddar to talk about how the company plans to grow the business of software-based therapeutics and how the first FDA authorized prescription digital therapeutics company will go about treating illnesses like insomnia and addiction. "These really are pieces of software. In many cases, they're apps and in the cases of our addiction products, these are based on something called cognitive behavioral therapy or CBT," he said. "These products change the patient's brain circuitry to help them be abstinent, to help them stay in treatment, and that's exactly what we see in randomized clinical trials and that's what we see in the real world." He also addressed the ongoing mental health crises brought on by the pandemic. **copy updated to remove IPO information as Pear Therapeutics went public in December**
Jake Carbone, senior data analyst at InfluenceMap joins Cheddar News to talk about a new report by The Guardian and InfluenceMap that reveals how companies are creating fossil fuel ads designed to look like Google search results.
Satellite launch service Virgin Orbit has gone public on the Nasdaq via a SPAC merger with NextGen Acquisitions with a valuation of about $3.2 billion. CEO Dan Hart joined Cheddar's "Between Bells" from in front of his LauncherOne rocket in New York City's Times Square to talk about what's next after the IPO, an upcoming "Above the Clouds" mission to deliver commercial and national security payloads, and the benefits of their rockets being launched from commercial 747 aircraft. "We can launch anywhere in the world," he said. "There are almost 80 space agencies across the world, for instance, and about 10 of them have space launch. We can give them a space flight capability overnight by taking a runway and turning it into a spaceport."
The year 2021 saw numerous natural disasters around the world, including extreme heat and wildfires, rare deep freezes, and historic flooding. This year's United Nations COP26 conference was key for getting world leaders on board with emissions reductions and other climate-focused policies as the UN Secretary-General said the agency's report on global warming is a 'code red for humanity.' In the U.S., President Joe Biden has focused most of his domestic agenda on slashing emissions and building climate-focused infrastructure. Guests from The Economist, UNC-Chapel Hill, Global Rescue, and more join Cheddar Climate's year-end special to discuss how the climate changed in 2021, and what to expect in 2022.
Digital mental health company Little Otter recently announced it closed a $22 million Series A round. Little Otter was founded in 2020 by a mother-daughter team, which based the company on the idea that a child's mental health can only be addressed by treating the whole family through technology available to everyone. Little Otter CEO and co-founder Rebecca Egger and her mother, Little Otter Chief Medical and Scientific Officer and co-founder Dr. Helen Egger joined Cheddar News' Closing Bell to discuss.
Among all the other events of the last few years, you may have missed this one: Spermageddon. This is the fun name for the idea that sperm counts among mainly ‘Western’ men are in freefall. The Spermageddon hype began with the publication of a 2017 study showing a nearly 60% drop in overall sperm counts in men living in North America, Europe, Australia, and New Zealand.
But four years later, it seems that Spermageddon has been overblown. By a lot. And all that hype has obscured the real issue behind declining male fertility.
Covid-19 has changed the way we view wellness. Jillian Hughes, communications director of Mental Health America, joins Cheddar News to discuss breaking the stigma around mental health. Justin Davis, CEO and co-founder of Spectrum Labs, weighs in on how social media impacts our wellbeing. Lastly, Precision Nutrition CEO Timothy Jones advices us on what trends to watch in 2022.
